Finn Thorup Sellebjerg

Research output

Research output per year 1997 2016 2017 2018 2020

• 124 Journal article
• 5 Letter
• 4 Conference abstract in journal
• 3 Book chapter
• 4 More
  • 3 Review
  • 1 Editorial

Research output per year

Research output per year

Search results

• 2016

  Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry

  Dreyer, L., Magyari, M., Laursen, B., Cordtz, R., Sellebjerg, F. & Locht, H., Apr 2016, In: Annals of the Rheumatic Diseases. 75, 4, p. 785-6 2 p.

  Research output: Contribution to journal › Letter › peer-review

  18 Citations (Scopus)

• Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry (DMSR)

  Dreyer, L., Magyari, M., Laursen, B., Cordtz, R., Sellebjerg, F. & Locht, H., 2016, In: Scandinavian Journal of Rheumatology. 45, sup128, 1 p., PP31.

  Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

• Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease

  Vinther-Jensen, T., Börnsen, L. S., Budtz-Jorgensen, E., Ammitzboll, C., Larsen, I. U., Hjermind, L. E., Sellebjerg, F. & Nielsen, J. E., 1 Dec 2016, In: Neurology: Neuroimmunology & Neuroinflammation. 3, 6, e287.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Huntington Disease 100%
  • Biomarkers 58%
  • Chitinase-3-Like Protein 1 45%
  • Intermediate Filaments 42%
  • Myelin Basic Protein 31%
  24 Citations (Scopus)

• Shift work at young age is associated with increased risk of multiple sclerosis in a Danish population

  Gustavsen, S., Søndergaard, H. B., Oturai, D. B., Laursen, B., Laursen, J. H., Magyari, M., Ullum, H., Larsen, M. H., Sellebjerg, F. & Oturai, A. B., 1 Sept 2016, In: Multiple Sclerosis and Related Disorders. 9, p. 104-109 6 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Multiple Sclerosis 100%
  • Population 44%
  • Life Style 15%
  • Logistic Models 12%
  • Odds Ratio 12%
  11 Citations (Scopus)

• Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis

  Petersen, E. R., Søndergaard, H. B., Oturai, A. B., Jensen, P. E. H., Sørensen, P. S., Sellebjerg, F. & Börnsen, L., Nov 2016, In: Multiple Sclerosis and Related Disorders. 10, p. 66-72 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Natalizumab 100%
  • Vascular Cell Adhesion Molecule-1 80%
  • Multiple Sclerosis 61%
  • Messenger RNA 39%
  • Serum 31%
  2 Citations (Scopus)

• Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab

  Laursen, J. H., Søndergaard, H. B., Sørensen, P. S., Sellebjerg, F. & Oturai, A. B., Nov 2016, In: Multiple Sclerosis and Related Disorders. 10, p. 169-173 5 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Natalizumab 100%
  • Relapsing-Remitting Multiple Sclerosis 86%
  • Vitamin D 64%
  • Recurrence 39%
  • Multiple Sclerosis 24%
  35 Citations (Scopus)
• 2015

  Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis

  Modvig, S., Degn, M., Roed, H., Sørensen, T. L., Larsson, H., Langkilde, A., Fredriksen, J. L. & Sellebjerg, F., 1 Dec 2015, In: Multiple Sclerosis Journal. 21, 14, p. 1761-1770

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Chitinases 100%
  • Optic Neuritis 88%
  • Intermediate Filaments 76%
  • Multiple Sclerosis 61%
  • Cerebrospinal Fluid 60%
  76 Citations (Scopus)

• Endogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis

  Börnsen, L., Christensen, J. R., Ratzer, R., Hedegaard, C. J., Søndergaard, H. B., Krakauer, M., Hesse, D., Nielsen, C. H., Sorensen, P. S. & Sellebjerg, F., 4 Mar 2015, In: P L o S One. 10, 3, p. 1-20 20 p., e0118830.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Interferons 100%
  • Multiple Sclerosis 87%
  • T-cells 82%
  • sclerosis 76%
  • myelin basic protein 75%
  15 Citations (Scopus)

• Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis

  Laursen, J. H., Søndergaard, H. B., Albrechtsen, A., Frikke-Schmidt, R., Koch-Henriksen, N., Sørensen, P. S., Sellebjerg, F. T. & Oturai, A. B., 1 Oct 2015, In: Multiple Sclerosis Journal. 21, 11, p. 1414-1422 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • 25-hydroxyvitamin D 100%
  • Multiple Sclerosis 75%
  • Single Nucleotide Polymorphism 71%
  • Vitamin D 47%
  • Genome-Wide Association Study 35%
  12 Citations (Scopus)

• Genetic variants are major determinants of CSF antibody levels in multiple sclerosis

  Goris, A., Pauwels, I., Gustavsen, M. W., van Son, B., Hilven, K., Bos, S. D., Celius, E. G., Berg-Hansen, P., Aarseth, J., Myhr, K-M., D'Alfonso, S., Barizzone, N., Leone, M. A., Martinelli Boneschi, F., Sorosina, M., Liberatore, G., Kockum, I., Olsson, T., Hillert, J., Alfredsson, L., & 27 othersBedri, S. K., Hemmer, B., Buck, D., Berthele, A., Knier, B., Biberacher, V., van Pesch, V., Sindic, C., Bang Oturai, A., Søndergaard, H. B., Sellebjerg, F., Jensen, P. E. H., Comabella, M., Montalban, X., Pérez-Boza, J., Malhotra, S., Lechner-Scott, J., Broadley, S., Slee, M., Taylor, B., Kermode, A. G., Gourraud, P-A., Sawcer, S. J., Andreassen, B. K., Dubois, B., Harbo, H. F. & International Multiple Sclerosis Genetics Consortium, 1 Mar 2015, In: Brain. 138, 3, p. 632-43 12 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Oligoclonal Bands 100%
  • Multiple Sclerosis 62%
  • Immunoglobulin G 53%
  • Antibodies 39%
  • Major Histocompatibility Complex 30%
  38 Citations (Scopus)

• Guidelines on Cerebrospinal Fluid Analysis

  Hegen, H., Teunissen, C. E., Sellebjerg, F., Tumani, H. & Deisenhammer, F., 1 Jan 2015, Cerebrospinal Fluid in Clinical Neurology. Deisenhammer, F., Sellebjerg, F., Teunissen, C. E. & Tumani, H. (eds.). Springer Science+Business Media, p. 407-428 22 p.

  Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review

  • Cerebrospinal Fluid 100%
  • Guidelines 73%
  • Serology 17%
  • Serum Albumin 16%
  • Leukocyte Count 15%
  1 Citation (Scopus)

• Immunoglobulins in Cerebrospinal Fluid

  Sellebjerg, F. T., 1 Jan 2015, Cerebrospinal Fluid in Clinical Neurology. Deisenhammer, F., Sellebjerg, F., Teunissen, C. E. & Tumani, H. (eds.). Cham Heidelberg New York Dordrecht London: Springer, p. 115-29 15 p.

  Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review

• Multiple sclerosis: A clinically useful genetic variant in multiple sclerosis?

  Sellebjerg, F. & Oturai, A. B., 9 Jul 2015, In: Nature Reviews. Neurology. 11, 7, p. 371-2 2 p.

  Research output: Contribution to journal › Review › peer-review

• Therapeutic interference with leukocyte recirculation in multiple sclerosis

  Sellebjerg, F. & Sørensen, P. S., 1 Mar 2015, In: European Journal of Neurology. 22, 3, p. 434-42 9 p.

  Research output: Contribution to journal › Review › peer-review

  • Natalizumab 100%
  • Fingolimod Hydrochloride 96%
  • Multiple Sclerosis 76%
  • Leukocytes 68%
  • Sphingosine-1-Phosphate Receptors 48%
  9 Citations (Scopus)
• 2014

  Clinical Relevance of Brain Volume Measures in Multiple Sclerosis

  De Stefano, N., Airas, L., Grigoriadis, N., Mattle, H. P., O'Riordan, J., Oreja-Guevara, C., Sellebjerg, F., Stankoff, B., Walczak, A., Wiendl, H. & Kieseier, B. C., Feb 2014, In: C N S Drugs. 28, 2, p. 147-156 10 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Multiple Sclerosis 100%
  • Brain 55%
  • Clinical Trials 20%
  • Gray Matter 10%
  • White Matter 9%
  189 Citations (Scopus)

• CLIPPERS among patients diagnosed with non-specific CNS neuroinflammatory diseases

  Kerrn-Jespersen, B. M., Lindelof, M., Illes, Z., Blaabjerg, M., Lund, E. L., Klausen, C., Christiansen, I., Sellebjerg, F. & Kondziella, D., 15 Aug 2014, In: Journal of the Neurological Sciences. 343, 1-2, p. 224-227 4 p.

  Research output: Contribution to journal › Letter › peer-review

  • Central Nervous System Diseases 100%
  • Steroids 68%
  • Demyelinating Diseases 57%
  • Neurosarcoidosis 57%
  • Inflammation 53%
  9 Citations (Scopus)

• Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development

  Hegen, H., Millonig, A., Bertolotto, A., Comabella, M., Giovanonni, G., Guger, M., Hoelzl, M., Khalil, M., Killestein, J., Lindberg, R., Malucchi, S., Mehling, M., Montalban, X., Polman, C. H., Rudzki, D., Schautzer, F., Sellebjerg, F., Sørensen, P. S. & Deisenhammer, F., Apr 2014, In: Multiple Sclerosis. 20, 5, p. 577-587 11 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Interferon-beta 100%
  • Neutralizing Antibodies 86%
  • Multiple Sclerosis 76%
  • Antibodies 47%
  • Biomarkers 14%
  36 Citations (Scopus)

• FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS

  Liu, Y., Carlsson, R., Comabella, M., Wang, J., Kosicki, M. K., Carrion, B., Hasan, M., Wu, X., Montalban, X., Dziegiel, M. H., Sellebjerg, F., Sørensen, P. S., Helin, K. & Navikas, S., Mar 2014, In: Nature Medicine.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Cell Death 100%
  • Regulatory T-Lymphocytes 93%
  • Immunosuppressive Agents 78%
  • Ligand 40%
  • Population 36%
  90 Citations (Scopus)

• Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis

  Ratzer, R., Romme Christensen, J., Romme Nielsen, B., Sørensen, P. S., Börnsen, L. & Sellebjerg, F., 15 Nov 2014, In: Journal of Neuroimmunology. 276, 1-2, p. 195-201 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Methylprednisolone 100%
  • Multiple Sclerosis 78%
  • Th17 Cells 70%
  • Blood Cells 24%
  • Leukocytes 23%
  6 Citations (Scopus)

• Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial

  Romme Christensen, J., Ratzer, R., Börnsen, L., Lyksborg, M., Garde, E., Dyrby, T. B., Siebner, H. R., Sorensen, P. S. & Sellebjerg, F., 29 Apr 2014, In: Neurology. 82, 17, p. 1499-1507 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Natalizumab 100%
  • Multiple Sclerosis 61%
  • Inflammation 29%
  • Biomarkers 25%
  • Osteopontin 23%
  80 Citations (Scopus)

• Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general

  Gustavsen, M. W., Viken, M. K., Celius, E. G., Berge, T., Mero, I-L., Berg-Hansen, P., Aarseth, J. H., Myhr, K-M., Søndergaard, H. B., Sellebjerg, F., Oturai, A. B., Hillert, J., Alfredsson, L., Olsson, T., Kockum, I., Lie, B. A. & Harbo, H. F., 15 Sept 2014, In: Journal of Neuroimmunology. 274, 1-2, p. 174-179 6 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • KIR Receptors 100%
  • Oligoclonal Bands 99%
  • Multiple Sclerosis 61%
  • Alleles 51%
  • Ligands 49%
  4 Citations (Scopus)

• Onset symptoms in paediatric multiple sclerosis

  Boesen, M. S., Sellebjerg, F. & Blinkenberg, M., Apr 2014, In: Danish Medical Journal. 61, 4, p. 1-4 4 p., A4800.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Multiple Sclerosis 100%
  • Pediatrics 72%
  • Confidence Intervals 33%
  • Cerebrospinal Fluid 16%
  • Oligoclonal Bands 13%
  6 Citations (Scopus)

• Prediction of response to interferon therapy in multiple sclerosis

  Sellebjerg, F., Søndergaard, H. B., Koch-Henriksen, N., Sørensen, P. S. & Oturai, A. B., 1 Oct 2014, In: Acta Neurologica Scandinavica. 130, 4, p. 268-275 8 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Interferons 100%
  • Multiple Sclerosis 96%
  • Glypicans 80%
  • Recurrence 54%
  • Single Nucleotide Polymorphism 34%
  20 Citations (Scopus)

• Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients

  Sorensen, P. S., Koch-Henriksen, N., Petersen, T., Ravnborg, M., Oturai, A. & Sellebjerg, F., Jun 2014, In: Journal of Neurology. 261, 6, p. 1170-1177 8 p.

  Research output: Contribution to journal › Letter › peer-review

  • Natalizumab 100%
  • Multiple Sclerosis 61%
  • Recurrence 39%
  • Confidence Intervals 11%
  • Therapeutics 11%
  90 Citations (Scopus)

• The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis

  Møller, M., Søndergaard, H. B., Koch-Henriksen, N., Sorensen, P. S., Sellebjerg, F. & Oturai, A. B., Jan 2014, In: Acta Neurologica Scandinavica. 129, 1, p. 27-31 5 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Natalizumab 100%
  • Chemokine Receptors 77%
  • Multiple Sclerosis 61%
  • Alleles 50%
  • Integrin alpha4beta1 14%
  7 Citations (Scopus)
• 2013

  Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

  Beecham, A. H., Patsopoulos, N. A., Xifara, D. K., Davis, M. F., Kemppinen, A., Cotsapas, C., Shah, T. S., Spencer, C., Booth, D., Goris, A., Oturai, A., Saarela, J., Fontaine, B., Hemmer, B., Martin, C., Zipp, F., D'Alfonso, S., Martinelli-Boneschi, F., Taylor, B., Harbo, H. F., & 174 othersKockum, I., Hillert, J., Olsson, T., Ban, M., Oksenberg, J. R., Hintzen, R., Barcellos, L. F., Agliardi, C., Alfredsson, L., Alizadeh, M., Anderson, C., Andrews, R., Søndergaard, H. B., Baker, A., Band, G., Baranzini, S. E., Barizzone, N., Barrett, J., Bellenguez, C., Bergamaschi, L., Bernardinelli, L., Berthele, A., Biberacher, V., Binder, T., Blackburn, H., Bomfim, I. L., Brambilla, P., Broadley, S., Brochet, B., Brundin, L., Buck, D., Butzkueven, H., Caillier, S. J., Camu, W., Carpentier, W., Cavalla, P., Celius, E. G., Coman, I., Comi, G., Corrado, L., Cosemans, L., Cournu-Rebeix, I., Cree, B. A. C., Cusi, D., Damotte, V., Defer, G., Delgado, S. R., Deloukas, P., di Sapio, A., Dilthey, A. T., Donnelly, P., Dubois, B., Duddy, M., Edkins, S., Elovaara, I., Esposito, F., Evangelou, N., Fiddes, B., Field, J., Franke, A., Freeman, C., Frohlich, I. Y., Galimberti, D., Gieger, C., Gourraud, P-A., Graetz, C., Graham, A., Grummel, V., Guaschino, C., Hadjixenofontos, A., Hakonarson, H., Halfpenny, C., Hall, G., Hall, P., Hamsten, A., Harley, J., Harrower, T., Hawkins, C., Hellenthal, G., Hillier, C., Hobart, J., Hoshi, M., Hunt, S. E., Jagodic, M., Jel?i?, I., Jochim, A., Kendall, B., Kermode, A., Kilpatrick, T., Koivisto, K., Konidari, I., Korn, T., Kronsbein, H., Langford, C., Larsson, M., Lathrop, M., Lebrun-Frenay, C., Lechner-Scott, J., Lee, M. H., Leone, M. A., Leppä, V., Liberatore, G., Lie, B. A., Lill, C. M., Lindén, M., Link, J., Luessi, F., Lycke, J., Macciardi, F., Männistö, S., Manrique, C. P., Martin, R., Martinelli, V., Mason, D., Mazibrada, G., McCabe, C., Mero, I-L., Mescheriakova, J., Moutsianas, L., Myhr, K-M., Nagels, G., Nicholas, R., Nilsson, P., Piehl, F., Pirinen, M., Price, S. E., Quach, H., Reunanen, M., Robberecht, W., Robertson, N. P., Rodegher, M., Rog, D., Salvetti, M., Schnetz-Boutaud, N. C., Sellebjerg, F., Selter, R. C., Schaefer, C., Shaunak, S., Shen, L., Shields, S., Siffrin, V., Slee, M., Sorensen, P. S., Sorosina, M., Sospedra, M., Spurkland, A., Strange, A., Sundqvist, E., Thijs, V., Thorpe, J., Ticca, A., Tienari, P., van Duijn, C., Visser, E. M., Vucic, S., Westerlind, H., Wiley, J. S., Wilkins, A., Wilson, J., Winkelmann, J., Zajicek, J., Zindler, E., Haines, J. L., Pericak-Vance, M. A., Ivinson, A. J., Stewart, G., Hafler, D., Hauser, S. L., Compston, A., McVean, G., De Jager, P., Sawcer, S. J., McCauley, J. L. & (IMSGC), I. M. S. G. C., Nov 2013, In: Nature Genetics. 45, 11, p. 1353-1360 8 p.

  Research output: Contribution to journal › Letter › peer-review

  • Multiple Sclerosis 100%
  • Genome-Wide Association Study 59%
  • Catalogs 35%
  • Major Histocompatibility Complex 28%
  796 Citations (Scopus)

• Blood-brain barrier permeability of normal appearing white matter in relapsing-remitting multiple sclerosis

  Lund, H., Krakauer, M., Skimminge, A., Sellebjerg, F., Garde, E., Siebner, H. R., Paulson, O. B., Hesse, D. & Hanson, L. G., 18 Feb 2013, In: P L o S One. 8, 2, 9 p., e56375.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Blood-Brain Barrier 100%
  • Multiple Sclerosis 88%
  • sclerosis 77%
  • blood-brain barrier 75%
  • DTPA 73%
  26 Citations (Scopus)

• Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab

  Blinkenberg, M., Sellebjerg, F., Leffers, A. M., Madsen, C. G. & Sørensen, P. S., Aug 2013, In: Multiple Sclerosis. 19, 9, p. 1226-1229 4 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Immune Reconstitution Inflammatory Syndrome 100%
  • Natalizumab 98%
  • Progressive Multifocal Leukoencephalopathy 94%
  • Multiple Sclerosis 60%
  • JC Virus 32%
  18 Citations (Scopus)

• CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis

  Romme Christensen, J., Börnsen, L., Khademi, M., Olsson, T., Jensen, P. E., Sørensen, P. S. & Sellebjerg, F., Jun 2013, In: Multiple Sclerosis.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Multiple Sclerosis 100%
  • Cerebrospinal Fluid 98%
  • Inflammation 66%
  • MBP-8298 65%
  • Biomarkers 64%
  55 Citations (Scopus)

• Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis

  Sellebjerg, F., Hesse, D., Limborg, S., Lund, H., Søndergaard, HB., Krakauer, M. & Sørensen, PS., Feb 2013, In: Multiple Sclerosis. 19, 2, p. 179-87 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Glatiramer Acetate 100%
  • Dendritic Cells 61%
  • Multiple Sclerosis 60%
  • Monocytes 56%
  • T-Lymphocytes 42%
  21 Citations (Scopus)

• Differential microRNA expression in blood in multiple sclerosis

  Søndergaard, H. B., Hesse, D., Krakauer, M., Sørensen, P. S. & Sellebjerg, F., Dec 2013, In: Multiple Sclerosis. 19, 14, p. 1849-1857 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Multiple Sclerosis 100%
  • MicroRNAs 95%
  • Biomarkers 26%
  • Relapsing-Remitting Multiple Sclerosis 25%
  • Blood Cells 25%
  74 Citations (Scopus)

• Gene expression analysis of relapsing– remitting, primary progressive and secondary progressive multiple sclerosis

  Ratzer, R., Søndergaard, H. B., Christensen, J. R., Börnsen, L. S., Borup, R., Sørensen, P. S. & Sellebjerg, F. T., Dec 2013, In: Multiple Sclerosis. 19, 14, p. 1841-1848 8 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Chronic Progressive Multiple Sclerosis 100%
  • Multiple Sclerosis 64%
  • Gene Expression 43%
  • Blood Cells 35%
  • Monocytes 24%
  22 Citations (Scopus)

• Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles

  Mero, I-L., Gustavsen, M. W., Sæther, H. S., Flåm, S. T., Berg-Hansen, P., Søndergaard, H. B., Jensen, P. E. H., Berge, T., Bjølgerud, A., Muggerud, A., Aarseth, J. H., Myhr, K-M., Celius, E. G., Sellebjerg, F., Hillert, J., Alfredsson, L., Olsson, T., Oturai, A. B., Kockum, I., Lie, B. A., & 3 othersAndreassen, B. K., Harbo, H. F. & Consortium, I. M. S. G., 5 Mar 2013, In: P L o S One. 8, 3, 9 p., e58352.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Multiple Sclerosis 100%
  • Oligoclonal Bands 90%
  • sclerosis 87%
  • Polymorphism 79%
  • Nucleotides 79%
  33 Citations (Scopus)

  388 Downloads (Pure)

• Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis

  Modvig, S., Degn, M., Horwitz, H., Cramer, S. P., Larsson, H. B. W., Wanscher, B., Sellebjerg, F. & Frederiksen, J. L., 8 Oct 2013, In: P L o S One. 8, 10, 8 p., e77163.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Inflammation 100%
  • Multiple Sclerosis 97%
  • Cerebrospinal fluid 89%
  • sclerosis 84%
  • Biomarkers 79%
  49 Citations (Scopus)

• Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression

  Romme Christensen, J., Börnsen, L., Ratzer, R., Piehl, F., Khademi, M., Olsson, T., Sørensen, P. S. & Sellebjerg, F., 1 Mar 2013, In: P L o S One. 8, 3, p. 1-11 11 p., e57820.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Inflammation 100%
  • Correlate 98%
  • Multiple Sclerosis 97%
  • B Cells 92%
  • sclerosis 84%
  135 Citations (Scopus)
• 2012

  Antithyroideaantistof hos to patienter med subakut dementiel udvikling, ataksi og myoklonus

  Translated title of the contribution: Anti-thyroid antibodies in two patients with subacute dementia, ataxia, and myoclonusKondziella, D., Hansen, K., Gonzalez, T., Gideon, P., Christiansen, I. & Sellebjerg, F., 2012, In: Ugeskrift for Laeger. 174, 9, p. 577-9 3 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Hunt's syndrome 100%
  • Hashimoto's encephalitis 88%
  • Creutzfeldt-Jakob Syndrome 77%
  • Anti-Idiotypic Antibodies 50%
  • Dementia 50%
  3 Citations (Scopus)

• Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis

  Romme Christensen, J., Börnsen, L., Hesse, D., Krakauer, M., Sørensen, P. S., Søndergaard, H. B. & Sellebjerg, F., 14 Sept 2012, In: Journal of Neuroinflammation. 9, p. 215

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Relapsing-Remitting Multiple Sclerosis 100%
  • Cytokines 49%
  • Cerebrospinal Fluid 42%
  • Lymphotoxin-alpha 31%
  • B-Lymphocytes 31%
  54 Citations (Scopus)

• Cerebral metabolism, magnetic resonance spectroscopy and cognitive dysfunction in early multiple sclerosis: an exploratory study

  Blinkenberg, M., Mathiesen, H. K., Tscherning, T., Jønsson, A., Svarer, C., Holm, S., Sellebjerg, F., Paulson, O. B., Hanson, L. G. & Sorensen, P. S., Jan 2012, In: Neurological Research. 34, 1, p. 52-8 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • N-acetylaspartate 100%
  • Multiple Sclerosis 68%
  • Magnetic Resonance Spectroscopy 65%
  • Cognitive Dysfunction 63%
  • Glucose 48%
  12 Citations (Scopus)

• Chronic cerebrospinal venous insufficiency and venous stenoses in multiple sclerosis

  Blinkenberg, M., Akeson, P., Sillesen, H., Lövgaard, S., Sellebjerg, F., Paulson, O. B., Siebner, H. R. & Sørensen, P. S., Dec 2012, In: Acta Neurologica Scandinavica. 126, 6, p. 421-7 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Venous Insufficiency 100%
  • Multiple Sclerosis 69%
  • Pathologic Constriction 62%
  • Jugular Veins 48%
  • Doppler Ultrasonography 18%
  29 Citations (Scopus)

• Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients

  Jensen, P. E. H., Sellebjerg, F., Søndergaard, H. B. & Sørensen, P. S., Oct 2012, In: European Journal of Neurology. 19, 10, p. 1311-7 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Neutralizing Antibodies 100%
  • Interferons 91%
  • Multiple Sclerosis 88%
  • Antibodies 55%
  • Messenger RNA 25%
  13 Citations (Scopus)

• Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis

  Börnsen, L., Christensen, J. R., Ratzer, R., Oturai, A. B., Sørensen, P. S., Søndergaard, H. B. & Sellebjerg, F., 30 Nov 2012, In: P L o S One. 7, 11, p. e47578

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Multiple Sclerosis 100%
  • T-cells 94%
  • Natalizumab 92%
  • sclerosis 87%
  • T-lymphocytes 58%
  40 Citations (Scopus)

• Endogenous and recombinant type I interferons and disease activity in multiple sclerosis

  Sellebjerg, F., Krakauer, M., Limborg, S., Hesse, D., Lund, H., Langkilde, A., Søndergaard, H. B. & Sørensen, P. S., 6 Jun 2012, In: P L o S One. 7, 6, p. e35927

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Interferons 100%
  • Multiple Sclerosis 87%
  • sclerosis 76%
  • Interferon Type I 66%
  • interferons 63%
  12 Citations (Scopus)

• FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4(+) CD25(high) T cells in multiple sclerosis

  Sellebjerg, F., Krakauer, M., Khademi, M., Olsson, T. & Sørensen, P. S., Nov 2012, In: Clinical and Experimental Immunology. 170, 2, p. 149-55 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • CTLA-4 Antigen 100%
  • Multiple Sclerosis 63%
  • T-Lymphocytes 44%
  • Gene Expression 43%
  • Regulatory T-Lymphocytes 28%
  24 Citations (Scopus)

• Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis

  Sellebjerg, F. T., Hedegaard, C. J., Krakauer, M., Hesse, D., Lund, H., Nielsen, C. H., Søndergaard, H. B. & Sørensen, P. S., Mar 2012, In: Multiple Sclerosis.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Glatiramer Acetate 100%
  • Multiple Sclerosis 60%
  • Gene Expression 41%
  • Antibodies 38%
  • Lymphotoxin-alpha 18%
  22 Citations (Scopus)

• Prediction of antibody persistency from antibody titres to natalizumab

  Jensen, P. E. H., Koch-Henriksen, N., Sellebjerg, F. & Sørensen, P. S., Oct 2012, In: Multiple Sclerosis. 18, 10, p. 1493-9 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Natalizumab 100%
  • Antibodies 38%
  • Anti-Idiotypic Antibodies 21%
  • Multiple Sclerosis 11%
  • Enzyme-Linked Immunosorbent Assay 8%
  19 Citations (Scopus)

• Progression and CSF Inflammation after Eradication of Oligoclonal Bands in an MS Patient Treated with Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma

  Braendstrup, P., Langkilde, A., Schreiber, K., Ravnborg, M., Sellebjerg, F. & Vindeløv, L., May 2012, In: Case Reports in Neurology. 4, 2, p. 101-6 6 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Oligoclonal Bands 100%
  • Follicular Lymphoma 86%
  • Cell Transplantation 76%
  • Allogeneic Cells 75%
  • Multiple Sclerosis 62%
  2 Citations (Scopus)
• 2011

  Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655

  Søndergaard, H. B., Sellebjerg, F., Hillert, J., Olsson, T., Kockum, I., Lindén, M., Mero, I-L., Myhr, K-M., Celius, E. G., Harbo, H. F., Christensen, J. R., Börnsen, L., Sørensen, P. S. & Oturai, A. B., Oct 2011, In: European Journal of Human Genetics. 19, 10, p. 1100-3 4 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Multiple Sclerosis 100%
  • Single Nucleotide Polymorphism 95%
  • Gene Expression 67%
  • Interferons 29%
  • Natural Killer T-Cells 19%
  5 Citations (Scopus)

• Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course

  Khademi, M., Kockum, I., Andersson, M. L., Iacobaeus, E., Brundin, L., Sellebjerg, F., Hillert, J., Piehl, F. & Olsson, T., Mar 2011, In: Multiple Sclerosis. 17, 3, p. 335-43 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Multiple Sclerosis 100%
  • Cerebrospinal Fluid 98%
  • Oligoclonal Bands 64%
  • Bacterial Infections 31%
  • Chronic Progressive Multiple Sclerosis 31%
  138 Citations (Scopus)

• Disease protection and interleukin-10 induction by endogenous interferon-β in multiple sclerosis?

  Hesse, D., Krakauer, M., Lund, H., Søndergaard, H. B., Limborg, S. J. W., Sørensen, P. S., Sellebjerg, F., Hesse, D., Krakauer, M., Søndergaard, H. B., Sørensen, P. S. & Sellebjerg, F. T., Feb 2011, In: European journal of neurology : the official journal of the European Federation of Neurological Societies. 18, 2, p. 266-72 6 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Interferons 100%
  • Interleukin-10 96%
  • Multiple Sclerosis 96%
  • Neutralizing Antibodies 32%
  • Interferon Type I 25%
  35 Citations (Scopus)

• Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

  Sawcer, S., Hellenthal, G., Pirinen, M., Spencer, C. C. A., Patsopoulos, N. A., Moutsianas, L., Dilthey, A., Su, Z., Freeman, C., Hunt, S. E., Edkins, S., Gray, E., Booth, D. R., Potter, S. C., Goris, A., Band, G., Oturai, A. B., Strange, A., Saarela, J., Bellenguez, C., & 31 othersFontaine, B., Gillman, M., Hemmer, B., Gwilliam, R., Zipp, F., Jayakumar, A., Martin, R., Leslie, S., Hawkins, S., Giannoulatou, E., D'alfonso, S., Blackburn, H., Boneschi, F. M., Liddle, J., Harbo, H. F., Perez, M. L., Spurkland, A., Waller, M. J., Mycko, M. P., Ricketts, M., Comabella, M., Hammond, N., Kockum, I., McCann, O. T., Ban, M., Whittaker, P., Kemppinen, A., Weston, P., Sellebjerg, F., Sørensen, P. S. & International Multiple Sclerosis Genetics Consortium, 11 Aug 2011, In: Nature. 476, 7359, p. 214-9 6 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Multiple Sclerosis 100%
  • Disease Susceptibility 83%
  • Genome-Wide Association Study 78%
  • Major Histocompatibility Complex 77%
  • HLA-DRB1 Chains 50%
  1819 Citations (Scopus)